You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Drug-Induced Liver Injury Assessment by Metabolomics: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Biochemistry & Molecular Biology
Contributor: Marta Moreno-Torres , Guillermo Quintás , José V. Castell

Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical industry. The current biochemical parameters for the detection of DILI are based on enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gammaglutamyl transpeptidase (GGT), alkaline phosphatase (ALP)) and bilirubin serum levels that are not specific of DILI and therefore there is an increasing interest on novel, specific, DILI biomarkers discovery. Metabolomics has emerged as a tool with a great potential for biomarker discovery, especially in disease diagnosis, and assessment of drug toxicity or efficacy. This review summarizes the multistep approaches in DILI biomarker research and discovery based on metabolomics and the principal outcomes from the research performed in this field.

  • Drug-induced liver injury
  • Diagnosis
  • hepatotoxicity
  • biomarkers
  • metabolomics
  • LC-MS

1. Drug-induced Liver Injury (DILI) and Its Clinical and Pharmaceutical Relevance

DILI is defined as a liver injury caused by pharmaceuticals, herbs, or other xenobiotics, resulting in abnormalities in liver tests or liver dysfunction [1]. DILI due to prescription or over-the-counter drugs is the most common manifestation of drug hepatotoxicity and a growing public health issue [2]. It represents the major reason for liver transplantation and is the leading cause of acute liver failure (ALF) in Europe and the United States. DILI accounts for 7–15% of the ALF cases (acetaminophen overdose excluded). Acetaminophen itself represents over 50% of ALF in adults in the USA, being the drug most frequently involved [3][4][5][6]. Unexpected adverse hepatic reactions to clinical drug treatments have an estimated incidence varying from 2.4 to 19 per 100,000 patients per year [7][8][9]. Its incidence and morbidity are rising in parallel to the introduction of new drugs, the extension of life expectancy, poly-medication in elderly people, and the widespread use of over-the-counter “alternative” medicines including herbal products.
On the other hand, DILI has also a significant relevance in the pharmaceutical industry business. Despite the rigorous steps in the early phases of drug development including the preclinical phase and the clinical trials [10], it is impossible to have complete information and 100% certainty about the safety of a new drug at the time of its approval. Thus, DILI is one of the most frequent and unexpected reasons for drug development discontinuation, drug non-approval, post-marketing regulatory additional actions, and withdrawal from the market [2]. Hence, the assessment and early recognition of hepatotoxicity of new drugs are of great interest to the pharmaceutical industry.

2. Types of DILI and Clinical Features of DILI

There are drugs (intrinsic hepatotoxins) that cause hepatocellular damage by defined mechanisms in a predictable dose-dependent manner and in all individuals exposed. This makes the identification of such compounds easier at the early stages of drug development. Others (idiosyncratic hepatotoxins) cause damage for reasons that are closer to the individual phenotypes rather than to the drug itself, and hence, the event is rare, unpredictable, and not always clearly related to dose, route, or treatment duration. Idiosyncratic hepatotoxicity can be classified into metabolic and immunological categories. In the first case, DILI susceptibility depends on a particular patient’s environmental setting (concomitant disease), individual’s genetic susceptibility, host-related (age, gender, and ethnicity), and drug-related factors (dose, metabolism, and lipophilicity) [11][12]. In the second case, the major player is the activation of the immune system recognizing drug-derived antigens on hepatocytes and triggering a hypersensitivity Type I or IV reaction that ultimately can evolve into an autoimmune disease [12]. Typically, idiosyncratic toxicity occurs with drugs and at doses otherwise well tolerated by the majority of patients [13].
Three patterns of damage are the hallmark for the classification of DILI, namely, hepatocellular, cholestatic, and mixed type, as adopted by the Council for International Organisations of Medical Sciences [14][15]. Hepatocellular DILI is characterised by a liver cell necrosis pattern, release of transaminases ALT and AST and lactate dehydrogenase (LDH), and inflammation, but only mild bile stasis. This hepatocellular pattern is present in acute hepatic necrosis, acute hepatitis, chronic hepatitis, and non-alcoholic steatohepatitis (NASH) [16]. On the other hand, the cholestatic DILI phenotype is characterised by bile production impairment and reflux with bile stasis, which affects ductal cells and the biliary tree with an increase in ALP and GGT in sera. Because of bile flux stasis, other conjugates normally excreted to bile are also increased in serum, (i.e., conjugated bilirubin). The mixed-type DILI shares features of both disease phenotypes and is typical of many drugs and the most frequent pattern of DILI, otherwise rarely occurring in other forms of acute liver disease.

3. The Diagnosis of DILI: Conventional Clinical and Biochemical Biomarkers

Currently, there are no specific biomarkers for the early and conclusive diagnosis and monitoring of DILI. Thus, the pathological examination of a liver biopsy remains the gold standard providing the most conclusive insight into the pathophysiological nature of a drug-induced liver damage event. Yet, it is not free from risks and side effects for the patient and therefore is not always applicable. In practical terms, DILI is diagnosed by excluding other putative liver diseases, and by the application of causality scales that assign a probability degree to an event as being caused by a drug [17]. The temporal relationship between drug intake and the clinical symptoms is determinant in the score provided by causality scales. However, reactions may occur from weeks to months after treatment initiation or even appear once the administration of the drug has been discontinued [18][19]. The situation becomes even more complex in multi- or poly-medicated patients and/or with concomitant comorbidities. In many cases, re-challenging with the drug, whenever acceptable, renders them unique and definitive proof to identify the drug responsible for DILI [20].
To assist in the classification of the different DILI phenotypes, serum enzymes AST, ALT, ALP, GGT and total bilirubin (TB) can be used. ALT levels are more liver-specific than AST, but are not aetiology specific [21][22]. ALP is also not liver-specific and can be considerably elevated in other liver non-related diseases [23]. Regarding bilirubin levels, they only increase when there has been extensive liver damage. Moreover, jaundice runs parallel to cholestasis in most but not in all DILI cases.
In this regard, Hy’s law is an empirical estimation of the severity and risk of suffering an ALF as a consequence of a DILI episode. It states that drug-induced jaundice together with hepatocellular injury, without a significant obstructive component, is an empirical indicator of the probability of suffering ALF. It is based on the evidence that jaundice as expressed by TB in blood, decreased hepatic function, expressed by the International Normalised Ratio of prothrombin time test (INR), and a high ratio of AST or ALT, can predict the risk of developing ALF. ALF is very likely to occur when hepatic injury (ALT/AST > 3 × upper limit of normal (ULN)), jaundice (TB > 2 × ULN), or liver dysfunction (INR > 1.5 × ULN) and in the absence of obstructive cholestasis (ALP < 2 × ULN) and excluded from other disease-induced liver damage.
Based on the ratio of ALT and ALP enzymes and their value over the upper normal levels, clinicians easily classify the various phenotypes of DILI using an R-value defined as [ALT value/ALT upper normal limit (UNL)]/[ALP value/ALP UNL]). DILI is assigned as hepatocellular when R ≥ 5, cholestatic when R ≤ 2, and mixed type if 2 < R < 5 [24]. The R index may display the same value, independently of the absolute magnitudes of ALT and ALP as far as their relative ratio remains constant and does not assist in better estimating the nature of the “mixed-type” DILI phenotype. In general, in the course of DILI, levels of serum liver enzymes do not correlate with the degree of hepatocyte metabolic dysfunction, histological patterns of damage, or severity , rather they increase only upon substantial and massive hepatocyte damage [25]. In addition, mitochondrial respiratory chain inhibition, or mitochondrial dysfunction that often occurs at the early stages of drug-induced injury is not accompanied by elevated ALT or ALP values [26], preventing an early diagnosis of DILI. These drawbacks limit the confident use of the R-score for a precise phenotype diagnosis and progression of DILI.
Several genetic and circulating biomarkers for the estimation of the risk of suffering a DILI event have been proposed by the large-scale initiative of the Safer and Faster Evidence-based Translation (SAFE-T) Consortium in Europe. These include glutamate dehydrogenase (GLDH), glutathione S-transferase, high-mobility group box-1 (HMGB-1), miRNA-122, full length, and caspase-cleaved keratin-18 (K-18) [27][28][29], different HLA alleles [30][31], and sorbitol dehydrogenase (SDH). However, altered levels of these biomarkers are not specific to DILI or liver disease [32].

4. Metabolomics in DILI Research and Diagnosis

4.1. Metabolomics vs. Transcriptomics and Proteomics in DILI Biomarker Discovery

The use of omics techniques for the identification of the biochemical changes caused by hepatotoxic drugs, and hence, uncovering new DILI biomarkers is an active field of research. In the past decade, transcriptomics and proteomics have been widely used for the study of hepatotoxicity [33][34]. These techniques help to visualise effects of hepatotoxins on gene activation and protein expression, but cannot reveal subtle changes in the cell’s metabolism, the end step of any disturbing action elicited by a toxicant. The liver plays a key role in the homeostasis of the whole organism, with many active metabolic processes susceptible to being altered by the noxious effects of a drug. Thus, it is reasonable to assume that the effects of a drug ultimately causing DILI are reflected in changes in the metabolome [26][35]. While genomics and proteomics describe what might be potentially happening, given that metabolites are the end products of the metabolic reaction pathways, metabolite alterations, and the metabolome provide the best comprehensive insight into what is actually happening as a consequence of a noxious stimulus [36]. They better represent the actual metabolic status of a cell or tissue being a relevant source of information to identify the molecular initiating events in the context of the Adverse Outcome Pathway (AOP) approach [37]. Metabolites are commonly present in many cell types, tissues, and organisms and are part of many conserved metabolic pathways; thus, the analysis and translation of results to humans are affordable [38].

Metabolomics also represents an interesting approach regarding toxicity response prediction, based on the identification of preclinical indicators of susceptibility to hepatotoxins that can be anticipated by assessing the basal pattern of endogenous metabolites prior to drug administration [39][40]. Indeed, several studies have evidenced that humans display characteristic and individual metabolic phenotypes or “metabotypes” [41][42][42] which are intended to be used to anticipate the distinct responses to drugs in drug metabolism, and therefore susceptibility to DILI, advocating for individualized drug therapies.

4.2. Metabolites Identified as Putative Biomarkers of DILI in Humans

Considerable advances have recently been made in metabolomics in the discovery of useful biomarkers. Here, we review the major outcomes of metabolomics studies performed for DILI evaluation. A literature search was conducted using the terms “metabolomics”, “DILI” and “humans” in the PUBMED, Web of Science, PubTator, and Embase databases. In vitro and animal studies were excluded from the revision. Despite some initial studies being performed with NMR, MS was the prominent methodology used in the vast majority of research since it provides different ionisation techniques, increasing the number of metabolites that can potentially be detected with enormous sensitivity and selectivity. Being an emerging area of research, the number of scientific reports is reduced. Table S1 (Supplementary Material) summarises metabolic alterations associated with DILI and provides a list of metabolites consistently reported between 2009 and 2021 in 25 clinical and experimental studies, considered as emerging circulating DILI biomarkers. Attention was paid principally to their links to the DILI and not to the drug causing the event. Among them, few studies addressed the identification of specific markers for DILI prediction or individual susceptibility determination [39][43][44][45][46] while the vast majority were focused on DILI diagnosis and follow-up [47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66].

Detailed information with the results, outcomes and conclusions of the review can be found at: doi: 10.3390/metabo12060564.

5. Conclusions and Future Perspectives

Great advances have been made in the applicability of MS-metabolomics for the diagnosis of DILI by examining urine, plasma, and serum human samples of patients. These biological samples carry over parts of the hepatocyte exometabolome that allows the identification of DILI-specific biomarkers. These research papers support the great potential of metabolomics as a major source of novel biomarkers for DILI diagnosis and susceptibility, type and severity of the response, and effects caused by a given drug therapy. Altogether, it can contribute to a better understanding of the DILI phenomena and increase safety scrutinization of drugs under development. Several metabolites appeared as statistically significant discriminants in those studies, demonstrating their potential as putative DILI biomarkers; however, up to today, there is not a unanimous agreement on a specific metabolic fingerprint that can be recommended for the routine diagnosis and prognosis of DILI in the clinics. Nevertheless, very promising steps forward have been undertaken and point at future clinical routine use. Inconsistencies among studies can be explained by several factors. First, the different methods applied for metabolomic analysis may influence the type and number of analytes detected and identified. Second, the majority of the studies clustered DILI and non-DILI patients without considering the DILI phenotypes and the causing agent that can belong to a wide range of pharmacological categories and, hence, influence distinct metabolic pathways. Third, the prevailing limitation for clinical verification of a novel biomarker is the requirement to test them in a meaningfully large and well-defined patient population, and here, both the number of individuals included in each cohort study and the number of studies performed so far are still insufficient to provide biomarker candidates with enough statistical discriminative power. Even more, not all studies claiming new biomarkers have proved the sensitivity and specificity of their candidate metabolites as diagnostic biomarkers of DILI. Fourth, the scope of the research differs among the studies. While some of them are focused on the identification of discriminating metabolites between DILI and non-DILI patients, others included distinct grades of DILI severity and even other types of liver diseases which difficults the identification of commonly agreed biomarkers. Therefore, there is still a need for standardised and multicentre studies to address these challenges in the field of DILI metabolomics. All this has prevented up to now, the widespread use of metabolomics-derived biomarkers in routine clinical practice. No less relevant is the fact that data analysis still requires technical expertise and highly experienced personnel. This will probably be made simpler when user-friendly analytical software for data processing will be developed and standardised. Notwithstanding the current limitations, some studies have made very significant advances in the way DILI can be approached from the metabolome analysis, not only to discriminate the phenotype, severity, and evolution of the disease but also to bring new insights to numerically describe the behaviour of a given drug in different patients. An important outcome is that focus should be put on the comparisons of the metabolic pathways altered in DILI rather than on a combination of individual metabolites. The influences of the methodology in biassing data having been retrieved from patients in different moments and with different analysers that tend to be minimised, reaching a comparable diagnosis for a given patient’s sample. The increasing applicability of metabolomics in biomedical research has led to the development of computational and visual tools such as the mummichog algorithm and pathway analysis, as well as tools for the comparison and meta-analysis of metabolomics results, which permit extracting meaningful and more reproducible information in this type of research than with the analysis of individual metabolite levels per se. Given the great possibilities that offer to combine physiological and metabolic pathway information, together with further technological innovation and larger cohorts of patients, the application of metabolomics will provide new findings of early specific markers of diagnostic, treatment, and prognosis of DILI.

This entry is adapted from the peer-reviewed paper 10.3390/metabo12060564

References

  1. J.S. Barkin; Etiology of New-Onset Jaundice: How Often Is It Caused by Idiosyncratic Drug-Induced Liver Injury in The United States?. Yearbook of Medicine 2008, 2008, 487-488, 10.1016/s0084-3873(08)79055-2.
  2. Paul A. Walker; Stephanie Ryder; Andrea Lavado; Clive Dilworth; Robert J. Riley; The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development. Archives of Toxicology 2020, 94, 2559-2585, 10.1007/s00204-020-02763-w.
  3. William J. Holubek; Susanne Kalman; Robert S. Hoffman; Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2006, 43, 880-880, 10.1002/hep.21106.
  4. George Ostapowicz; Robert J. Fontana; Frank V. Schiødt; Anne Larson; Timothy J. Davern; Steven H.B. Han; Timothy M. McCashland; A. Obaid Shakil; J. Eileen Hay; Linda Hynan; et al. Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States. Annals of Internal Medicine 2002, 137, 947-954, 10.7326/0003-4819-137-12-200212170-00007.
  5. Einar Björnsson; Pernilla Jerlstad; Annika Bergqvist; Rolf Olsson; Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scandinavian Journal of Gastroenterology 2005, 40, 1095-1101, 10.1080/00365520510023846.
  6. Mark W. Russo; Joseph A. Galanko; Roshan Shrestha; Michael W. Fried; Paul Watkins; Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplantation 2004, 10, 1018-1023, 10.1002/lt.20204.
  7. Einar S. Björnsson; Ottar M. Bergmann; Helgi K. Björnsson; Runar B. Kvaran; Sigurdur Olafsson; Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland. Gastroenterology 2013, 144, 1419-1425.e3, 10.1053/j.gastro.2013.02.006.
  8. Varsha Saxena; Ashish Gupta; G. A. Nagana Gowda; Rajan Saxena; S. K. Yachha; C. L. Khetrapal; 1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure. NMR in Biomedicine 2006, 19, 521-526, 10.1002/nbm.1034.
  9. Francisco J. De Abajo; Dolores Montero; Mariano Madurga; Luis A. Garcia Rodriguez; Acute and clinically relevant drug-induced liver injury: a population based case-control study. British Journal of Clinical Pharmacology 2004, 58, 71-80, 10.1111/j.1365-2125.2004.02133.x.
  10. Arie Regev; Drug-Induced Liver Injury and Drug Development: Industry Perspective. Seminars in Liver Disease 2014, 34, 227-239, 10.1055/s-0034-1375962.
  11. Minjun Chen; Ayako Suzuki; Jürgen Borlak; Raúl J. Andrade; M Isabel Lucena; Drug-induced liver injury: Interactions between drug properties and host factors. Journal of Hepatology 2015, 63, 503-514, 10.1016/j.jhep.2015.04.016.
  12. Jose V. Castell; Allergic hepatitis: a drug-mediated organ-specific immune reaction.. Clinical & Experimental Allergy 1998, 28, 258-65, 10.1097/01.all.0000235898.80052.80.
  13. Jose V. Castell; Marta Castell; Allergic hepatitis induced by drugs. Current Opinion in Allergy & Clinical Immunology 2006, 6, 258-265, 10.1097/01.all.0000235898.80052.80.
  14. Yue-Cheng Yu; Drug-induced Liver Injury (DILI) Study Group; Yi-Min Mao; Cheng-Wei Chen; Jin-Jun Chen; Jun Chen; Wen-Ming Cong; Yang Ding; Zhong-Ping Duan; Qing-Chun Fu; et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatology International 2017, 11, 221-241, 10.1007/s12072-017-9793-2.
  15. Naemat Sandhu; Victor Navarro; Drug‐Induced Liver Injury in GI Practice. Hepatology Communications 2020, 4, 631-645, 10.1002/hep4.1503.
  16. David E Kleiner; The Pathology of Drug-Induced Liver Injury. Seminars in Liver Disease 2009, 29, 364-372, 10.1055/s-0029-1240005.
  17. Hans L. Tillmann; Ayako Suzuki; Huiman X. Barnhart; Jose Serrano; Don C. Rockey; Tools for causality assessment in drug-induced liver disease. Current Opinion in Gastroenterology 2019, 35, 183-190, 10.1097/mog.0000000000000526.
  18. M. Isabel Lucena; Raúl J. Andrade; M. Carmen Fernández; Ketevan Pachkoria; Gloria Pelaez; José A. Durán; Macarena Villar; Luis Rodrigo; Manuel Romero-Gomez; Ramón Planas; et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. Hepatology 2006, 44, 850-856, 10.1002/hep.21324.
  19. M. Isabel Lucena; Raúl J. Andrade; Luis Rodrigo; Javier Salmerón; Arancha Alvarez; M. J. Lopez-Garrido; Raquel Camargo; Ramiro Alcantára; Trovafloxacin-Induced Acute Hepatitis. Clinical Infectious Diseases 2000, 30, 400-401, 10.1086/313680.
  20. William M. Lee; John R. Senior; Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions. Toxicologic Pathology 2005, 33, 155-164, 10.1080/01926230590522356.
  21. Mohammed Ibn-Mas’Ud Danjuma; Jamal Sajid; Haajra Fatima; Abdel-Naser Elzouki; Novel biomarkers for potential risk stratification of drug induced liver injury (DILI). Medicine 2019, 98, e18322, 10.1097/md.0000000000018322.
  22. P B Watkins; Managing the risk of drug-induced liver injury.. Clinical Pharmacology & Therapeutics 2013, 94, 629-31, 10.1038/clpt.2013.182.
  23. Robert J. Fontana; Paul H. Hayashi; Jiezhun Gu; K. Rajender Reddy; Huiman Barnhart; Paul B. Watkins; Jose Serrano; William M. Lee; Naga Chalasani; Andrew Stolz; et al. Idiosyncratic Drug-Induced Liver Injury Is Associated With Substantial Morbidity and Mortality Within 6 Months From Onset. Gastroenterology 2014, 147, 96-108.e4, 10.1053/j.gastro.2014.03.045.
  24. Harshad Devarbhavi; An Update on Drug-induced Liver Injury. Journal of Clinical and Experimental Hepatology 2012, 2, 247-259, 10.1016/j.jceh.2012.05.002.
  25. David E. Amacher; Shelli J. Schomaker; Jiri Aubrecht; Development of Blood Biomarkers for Drug-Induced Liver Injury: An Evaluation of Their Potential for Risk Assessment and Diagnostics. Molecular Diagnosis & Therapy 2013, 17, 343-354, 10.1007/s40291-013-0049-0.
  26. S Russmann; G A Kullak-Ublick; I Grattagliano; Current concepts of mechanisms in drug-induced hepatotoxicity. Current Medicinal Chemistry 1970, 16, 3041-3053, 10.5167/uzh-20361.
  27. Daniel J. Antoine; James W. Dear; Philip Starkey Lewis; Vivien Platt; Judy Coyle; Moyra Masson; Ruben H. Thanacoody; Alasdair J. Gray; David J. Webb; Jonathan G. Moggs; et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen‐induced acute liver injury at first presentation to hospital. Hepatology 2013, 58, 777-787, 10.1002/hep.26294.
  28. Rachel J. Church; Gerd A. Kullak‐Ublick; Jiri Aubrecht; Herbert L. Bonkovsky; Naga Chalasani; Robert J. Fontana; Jens C. Goepfert; Frances Hackman; Nicholas M. P. King; Simon Kirby; et al. Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort. Hepatology 2018, 69, 760-773, 10.1002/hep.29802.
  29. Siyu Fu; Dongbo Wu; Wei Jiang; Juan Li; Jiang Long; Chengyao Jia; TaoYou Zhou; Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives. Frontiers in Pharmacology 2020, 10, 1667, 10.3389/fphar.2019.01667.
  30. Ann K Daly; for the DILIGEN study; Peter T Donaldson; Pallav Bhatnagar; Yufeng Shen; Itsik Pe'Er; Aris Floratos; Mark J Daly; David B Goldstein; Sally John; et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics 2009, 41, 816-819, 10.1038/ng.379.
  31. Jonathan B Singer; Steve Lewitzky; Elisabeth Leroy; Fan Yang; Xiaojun Zhao; Lloyd Klickstein; Timothy M Wright; Joanne Meyer; Charles A Paulding; A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nature Genetics 2010, 42, 711-714, 10.1038/ng.632.
  32. Nigel J. Waters; Catherine J. Waterfield; R. Duncan Farrant; And Elaine Holmes; Jeremy K. Nicholson; Integrated Metabonomic Analysis of Bromobenzene-Induced Hepatotoxicity: Novel Induction of 5-Oxoprolinosis. Journal of Proteome Research 2006, 5, 1448-1459, 10.1021/pr060024q.
  33. Vivek C. Abraham; Danli L. Towne; Jeffrey F. Waring; Usha Warrior; David J. Burns; Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans. SLAS Discovery 2008, 13, 527-537, 10.1177/1087057108318428.
  34. Marta Benet; Marta Moya; M. Teresa Donato; Agustín Lahoz; David Hervás; Carla Guzmán; M. José Gómez-Lechón; José Vicente Castell; Ramiro Jover; A simple transcriptomic signature able to predict drug-induced hepatic steatosis. Archives of Toxicology 2014, 88, 967-982, 10.1007/s00204-014-1197-7.
  35. Wissam Bleibel; Stephen Kim; Karl D’Silva; Eric R. Lemmer; Drug-Induced Liver Injury: Review Article. Digestive Diseases and Sciences 2007, 52, 2463-2471, 10.1007/s10620-006-9472-y.
  36. Paula Iruzubieta; María Teresa Arias-Loste; Lucí Barbier-Torres; Maria Luz Martinez Chantar; Javier Crespo; The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?. BioMed Research International 2015, 2015, 1-8, 10.1155/2015/386186.
  37. Marco Oldiges; Stephan Lütz; Simon Pflug; Kirsten Schroer; Nadine Stein; Christiane Wiendahl; Metabolomics: current state and evolving methodologies and tools. Applied Microbiology and Biotechnology 2007, 76, 495-511, 10.1007/s00253-007-1029-2.
  38. R Goodacre; Metabolomics by numbers: acquiring and understanding global metabolite data. Trends in Biotechnology 2004, 22, 245-252, 10.1016/s0167-7799(04)00081-2.
  39. T. Andrew Clayton; David Baker; John C. Lindon; Jeremy R. Everett; Jeremy K. Nicholson; Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proceedings of the National Academy of Sciences 2009, 106, 14728-14733, 10.1073/pnas.0904489106.
  40. Yanru Liu; Rongqing Huang; Lijun Liu; Jiangnan Peng; Bingkun Xiao; Jianyun Yang; Zhenchun Miao; Honglin Huang; Metabonomics study of urine from Sprague–Dawley rats exposed to Huang-yao-zi using 1H NMR spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 2010, 52, 136-141, 10.1016/j.jpba.2009.12.026.
  41. Chunfeng Lu; Yimei Wang; Zhiguo Sheng; Gang Liu; Ze Fu; Jing Zhao; Jun Zhao; Xianzhong Yan; Benzhan Zhu; Shuangqing Peng; et al. NMR-based metabonomic analysis of the hepatotoxicity induced by combined exposure to PCBs and TCDD in rats. Toxicology and Applied Pharmacology 2010, 248, 178-184, 10.1016/j.taap.2010.07.020.
  42. Noriaki Shima; Izuru Miyawaki; Kiyoko Bando; Hiroshi Horie; Kei Zaitsu; Munehiro Katagi; Takeshi Bamba; Hitoshi Tsuchihashi; Eiichiro Fukusaki; Influences of methamphetamine-induced acute intoxication on urinary and plasma metabolic profiles in the rat. Toxicology 2011, 287, 29-37, 10.1016/j.tox.2011.05.012.
  43. J H Winnike; Z Li; F A Wright; J M Macdonald; T M O'connell; P B Watkins; Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans. Clinical Pharmacology & Therapeutics 2010, 88, 45-51, 10.1038/clpt.2009.240.
  44. Ulf Andersson; Johan Lindberg; Shunghuang Wang; Raji Balasubramanian; Maritha Marcusson-Ståhl; Mira Hannula; Chenhui Zeng; Peter J. Juhasz; Johan Kolmert; Jonas Bäckström; et al. A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers 2009, 0, -16, 10.1080/13547500903261354.
  45. Le Zhang; Ming Niu; Ai-Wu Wei; Jin-Fa Tang; Can Tu; Zhao-Fang Bai; Zheng-Sheng Zou; Xiao-He Xiao; You-Ping Liu; Jia-Bo Wang; et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum. Archives of Toxicology 2019, 94, 245-256, 10.1007/s00204-019-02595-3.
  46. Brandon J. Sonn; Kennon J. Heard; Susan M. Heard; Angelo D’Alessandro; Kate M. Reynolds; Richard C. Dart; Barry H. Rumack; Andrew A. Monte; Metabolomic markers predictive of hepatic adaptation to therapeutic dosing of acetaminophen. Clinical Toxicology 2021, 60, 221-230, 10.1080/15563650.2021.1925686.
  47. Rick D. Fannin; Mark Russo; Thomas M. O'connell; Kevin Gerrish; Jason H. Winnike; Jeffrey Macdonald; Jack Newton; Shahid Malik; Stella O. Sieber; Joel Parker; et al. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology 2009, 51, 227-236, 10.1002/hep.23330.
  48. Sudeepa Bhattacharyya; Lisa Pence; Richard Beger; Shubhra Chaudhuri; Sandra McCullough; Ke Yan; Pippa Simpson; Leah Hennings; Jack Hinson; Laura James; et al. Acylcarnitine Profiles in Acetaminophen Toxicity in the Mouse: Comparison to Toxicity, Metabolism and Hepatocyte Regeneration. Metabolites 2013, 3, 606-622, 10.3390/metabo3030606.
  49. Mitchell R. McGill; Feng Li; Matthew R. Sharpe; C. David Williams; Steven C. Curry; Xiaochao Ma; Hartmut Jaeschke; Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans. Archives of Toxicology 2013, 88, 391-401, 10.1007/s00204-013-1118-1.
  50. Taoguang Huo; Xi Chen; Xiumei Lu; Lianyue Qu; Yang Liu; Shuang Cai; An effective assessment of valproate sodium-induced hepatotoxicity with UPLC–MS and 1HNMR-based metabonomics approach. Journal of Chromatography B 2014, 969, 109-116, 10.1016/j.jchromb.2014.08.011.
  51. Benjamin L. Woolbright; Mitchell R. McGill; Vincent S. Staggs; Robert D. Winefield; Parviz Gholami; Mojtaba Olyaee; Matthew R. Sharpe; Steven C. Curry; William M. Lee; Hartmut Jaeschke; et al. Glycodeoxycholic Acid Levels as Prognostic Biomarker in Acetaminophen-Induced Acute Liver Failure Patients. Toxicological Sciences 2014, 142, 436-444, 10.1093/toxsci/kfu195.
  52. Laura James; Ke Yan; Lisa Pence; Pippa Simpson; Sudeepa Bhattacharyya; Pritmohinder Gill; Lynda Letzig; Gregory Kearns; Richard Beger; Comparison of Bile Acids and Acetaminophen Protein Adducts in Children and Adolescents with Acetaminophen Toxicity. PLOS ONE 2015, 10, e0131010, 10.1371/journal.pone.0131010.
  53. Jiabo Wang; Zhijie Ma; Ming Niu; Yun Zhu; Qingsheng Liang; Yanling Zhao; Jingyuan Song; Zhaofang Bai; Yaming Zhang; Ping Zhang; et al. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum. Frontiers of Medicine 2015, 9, 457-467, 10.1007/s11684-015-0417-8.
  54. Sudeepa Bhattacharyya; Lisa Pence; Ke Yan; Pritmohinder Gill; Chunqiao Luo; Lynda G. Letzig; Pippa M. Simpson; Gregory L. Kearns; Richard D. Beger; Laura P. James; et al. Targeted metabolomic profiling indicates structure-based perturbations in serum phospholipids in children with acetaminophen overdose. Toxicology Reports 2016, 3, 747-755, 10.1016/j.toxrep.2016.08.004.
  55. Laura K. Schnackenberg; Jinchun Sun; Sudeepa Bhattacharyya; Pritmohinder Gill; Laura P. James; Richard D. Beger; Metabolomics Analysis of Urine Samples from Children after Acetaminophen Overdose. Metabolites 2017, 7, 46, 10.3390/metabo7030046.
  56. J Lee; S C Ji; B Kim; S Yi; K H Shin; J Y Cho; K S Lim; S H Lee; S H Yoon; J Y Chung; et al. Exploration of Biomarkers for Amoxicillin/Clavulanate‐Induced Liver Injury: Multi‐Omics Approaches. Clinical and Translational Science 2016, 10, 163-171, 10.1111/cts.12425.
  57. Jun Cao; Yijun Mi; Cuilin Shi; Yicong Bian; Chenrong Huang; Zhijian Ye; Linsheng Liu; Liyan Miao; First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform. Biochemical and Biophysical Research Communications 2018, 497, 485-491, 10.1016/j.bbrc.2018.02.030.
  58. Zhenhua Ma; Xiaomei Wang; Peiyuan Yin; Ruihong Wu; Lina Zhou; Guowang Xu; Junqi Niu; Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. Medicine 2019, 98, e16717, 10.1097/md.0000000000016717.
  59. Zhongyang Xie; Ermei Chen; Xiaoxi Ouyang; Xiaowei Xu; Shanshan Ma; Feiyang Ji; Daxian Wu; Sainan Zhang; Yalei Zhao; Lanjuan Li; et al. Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury. Journal of Proteome Research 2019, 18, 2514-2524, 10.1021/acs.jproteome.9b00047.
  60. Kosuke Saito; Tatehiro Kagawa; Keiji Tsuji; Yuji Kumagai; Ken Sato; Shotaro Sakisaka; Naoya Sakamoto; Mitsuhiko Aiso; Shunji Hirose; Nami Mori; et al. Plasma Lipid Profiling of Three Types of Drug-Induced Liver Injury in Japanese Patients: A Preliminary Study. Metabolites 2020, 10, 355, 10.3390/metabo10090355.
  61. Ying Huang; Xu Zhao; Zi-Teng Zhang; Shuai-Shuai Chen; Shan-Shan Li; Zhuo Shi; Jing Jing; Ang Huang; Yu-Ming Guo; Zhao-Fang Bai; et al. Metabolomics Profiling and Diagnosis Biomarkers Searching for Drug-Induced Liver Injury Implicated to Polygonum multiflorum: A Cross-Sectional Cohort Study. Frontiers in Medicine 2020, 7, 858, 10.3389/fmed.2020.592434.
  62. Shuai-Shuai Chen; Ying Huang; Yu-Ming Guo; Shan-Shan Li; Zhuo Shi; Ming Niu; Zheng-Sheng Zou; Xiao-He Xiao; Jia-Bo Wang; Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis. Frontiers in Medicine 2021, 8, 640799, 10.3389/fmed.2021.640799.
  63. Guillermo Quintás; Teresa Martínez-Sena; Isabel Conde; Eugenia Pareja Ibars; Jos Kleinjans; José V. Castell; Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes. Archives of Toxicology 2021, 95, 3049-3062, 10.1007/s00204-021-03114-z.
  64. Zhongyang Xie; Lingjian Zhang; Ermei Chen; Juan Lu; Lanlan Xiao; Qiuhong Liu; Danhua Zhu; Fen Zhang; Xiaowei Xu; Lanjuan Li; et al. Targeted Metabolomics Analysis of Bile Acids in Patients with Idiosyncratic Drug-Induced Liver Injury. Metabolites 2021, 11, 852, 10.3390/metabo11120852.
  65. Tomoyoshi Soga; Masahiro Sugimoto; Masashi Honma; Masayo Mori; Kaori Igarashi; Kasumi Kashikura; Satsuki Ikeda; Akiyoshi Hirayama; Takehito Yamamoto; Haruhiko Yoshida; et al. Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. Journal of Hepatology 2011, 55, 896-905, 10.1016/j.jhep.2011.01.031.
  66. Ji Won Kim; Sung Ha Ryu; Siwon Kim; Hae Won Lee; Mi-Sun Lim; Sook Jin Seong; Suhkmann Kim; Young-Ran Yoon; Kyu-Bong Kim; Pattern Recognition Analysis for Hepatotoxicity Induced by Acetaminophen Using Plasma and Urinary 1H NMR-Based Metabolomics in Humans. Analytical Chemistry 2013, 85, 11326-11334, 10.1021/ac402390q.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Academic Video Service
Feedback